Stocktoria
Crinetics Pharmaceuticals, Inc. CRNX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-07-18
Crinetics Pharmaceuticals, Inc. statistics & valuation
Market cap$3.9B
P / B3.9×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| Net margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.3% |
| FCF margin | -4985.5% | -22525.3% | -4318.1% | -2467.0% | -8258.3% |
| Return on assets | -41.3% | -20.8% | -33.8% | -46.5% | -30.7% |
| Return on equity | -46.9% | -22.5% | -39.8% | -51.8% | -32.4% |
| Current ratio | 12.32 | 23.04 | 13.07 | 12.45 | 21.55 |
| Revenue growth | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% |
Source: SEC EDGAR filings · CIK 0001658247 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.